Skip to main content
OpenTrials
Completed

NCT Number: NCT02395926

To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers

Choline alfoscerate(L-alfa glycerylphosphorylcholine) is a natural compound found in the brain and breast. Choline alfoscerate contains 40.8% of choline and has a produrig structure and separated by a precursor of choline and nerve cell membrane precursor of acetylcholine glycerophosphate. Choline alfoscerate Colin normalization of nerve pathways, nerve cell membrane play and acetylcholine receptor function secondary symptoms caused by cerebrovascular deficiency and indirectly through activation of metabolism, has a degenerative effect on the brain organic mental syndrome.

Currently marketed oral choline alfoscerate received a geriatric cognitive impairment, secondary symptoms and degeneration, or soft capsule is authorized to prescription drugs for degenerative brain organic mental syndrome caused by cerebrovascular deficiency. Gliatilin soft capsules containing 400 mg per 1 capsule 2-3 times one days're supposed to take when considering optimal convenience and efficiency of the drug in patients with the development of sustained release formulations that can be maintained for a long period of time, a certain concentration is required. Accordingly, the modern drug by reducing the frequency of administration a day circuit is to develop a sustained release formulation of choline alfoscerate HT-003 600 mg medication compliance for the purpose of raising. 2 tablets at a time (600 mg x 2) can be taken one day to 1200 mg is required by taking.

Therefore, for the development of sustained release formulation, the test in healthy adult male volunteers targets choline alfoscerate soft capsule formulation of 400mg 3 times per 1 day and sustained-release tablet 600mg 2time per 1 day, pharmacokinetic properties and safety of a single dose should be evaluated when compared.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Male

Age range

20 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects between the ages of 20 and 55 years, inclusive
  • BMI>=19kg/m2, <=27kg/m2

*body mass index (kg/m2) = weight (kg)/ [(height (m)2)

  • Voluntary written consent by the parties that the ability and willingness to participate during the entire period of the test

Exclusion criteria

  • Subjects who has history or clinically significant disease about liver, kidney, digestive, respiratory, musculoskeletal, endocrine, neuropsychiatric, blood•tumor type, cardiovascular disease.
  • A GFR of less than 60ml/min person, calculated by the MDRD (Modification of Diet in Renal Disease)

※ MDRD equation (mL/min/1.73m2) : GFR = 175 x Scr-1.154 x age-0.203

  • Systolic blood pressure less than 90 mmHg in vital signs is 150 mmHg or diastolic blood pressure less than 50 mmHg or higher or numerical characters shown equal to at least 100 mmHg
  • Subjects with known for hypersensitivity reaction to components of the investigational drug
  • Subjects who has history of drug abuse, shows positive in urine drug screening test
  • Use of any prescription medication within 14 days prior to study medication dosing or use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing
  • Participation in any clinical investigation within 60days prior to study medication dosing
  • Subjects with whole blood donation within 60days, component blood donation within 30days
  • Caffeine-containing beverages (coffee, tea, cola) intake or grapefruit / orange juice who exceed the average daily intake of 4 cups.
  • Subjects who intake average alcohol consumption per week exceeds 140g or cannot be a non-alcohol during the hospital stay.
  • Subjects who exceed the average daily smoke of 10 cigarettes or cannot be a non-smoking during the hospital stay
  • Subjects who cannot limit the choline-containing food (liver, cocoa, bean, chocolate, otmil etc), from admitted to the hospital the day before
  • Subjects who shows positive in serum test (hepatitis B, C, HIV)
  • Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator

Treatment and study plan

Choline CR 600mg

Drug

HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00

Gliatilin 400mg

Drug

Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00

Primary outcomes

  1. Cmax

    Time frame: in 24hr after administration

  2. AUClast

    Time frame: in 24hr after administration

Secondary outcomes

  1. baseline-corrected Cmax

    Time frame: in 24hr after administration and before administration

  2. baseline-corrected AUClast

    Time frame: in 24hr after administration and before administration

  3. Tmax

    Time frame: in 24hr after administration and before administration

Sponsors and collaborators

Lead sponsor

Hyundai Pharmaceutical Co., LTD.

Industry

Registry information

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Mar 24, 2015
Registry last updated
Mar 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.